Bacterial and Plasmid Vectors Global Market Report 2023: Increasing Prevalence of Cancer and Infectious Diseases Drives Growth


Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Bacterial And Plasmid Vectors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global bacterial & plasmid vectors market is expected to grow from $0.51 billion in 2021 to $0.57 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The bacterial & plasmid vectors market is expected to reach $0.92 billion in 2026 at a CAGR of 12.6%.

Major players in the bacterial & plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Bacterial and plasmid vectors refer to the means by which recombinant DNA is introduced into a host cell and are essential to molecular cloning. It is basically a process of creating DNA molecules and introducing them into a host cell. These vectors are used to deliver recombinant DNA into bacteria so they can express proteins.

North America was the largest region in the bacterial & plasmid vectors market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the bacterial & plasmid vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of hosts in bacterial & plasmid vectors are E.coli expression vectors and other bacterial expression vectors. The E. coli expression system enables rapid recombinant protein expression and subsequent large-scale, cost-effective production. For non-glycosylated proteins, this technique is ideal for antigen expression and functional protein expression. The different applications include genetics, molecular biology, bioinformatics, and others and involve various sectors such as hospitals, homecare, specialty clinics, and others.

Increasing the prevalence of cancer and infectious diseases is anticipated to boost the demand for the bacterial & plasmid vectors market over the coming years. Bacteria are used as vectors for the delivery of recombinant proteins into target cells for the treatment of cancer and various infectious diseases.

According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, in 2020, the total cancer burden in the world increased to 19.3 million new cases and is predicted to rise to 28.4 million new cancer cases in 2040. Therefore, the growing prevalence of cancer and various infectious diseases and surging demand for bacterial & plasmid vectors for gene therapy is projected to propel the market revenues for the bacterial & plasmid vectors market.

The high cost of gene therapy is expected to limit the growth of the bacterial & plasmid vectors market during the forecast period. Gene therapy utilizes genuine genes to prevent or treat diseases that utilize bacteria or plasmids as vectors. The cost of gene therapy treatments approved by the Food and Drug Administration is between $0.3 million and $2.1 million.

Moreover, the cost of Luxturna gene therapy for certain inherited retinal diseases (IRDs) is $0.4 million per eye, and LentiGlobin a gene therapy by Bluebird Bio designed to increase the levels of hemoglobin costs around $2.1 million. Stringent government regulations, long approval processes, and production costs are the major factors leading to the high cost of gene therapy. Thus, the high cost of gene therapy is to hinder the growth of the bacterial & plasmid vectors market shortly.

The focus areas for many companies in the bacterial and plasmid vectors market have shifted to increasing mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets.

For instance, Vectalys, a France-based company engaged in manufacturing and commercializing lentiviral vectors for gene delivery, and FlashCell, a company engineering non-integrating lentiviral delivered RNA therapeutics announced their merger to create a new gene therapy company- Flash Therapeutics.

The countries covered in the bacterial & plasmid vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products.

Key Attributes:

Report AttributeDetails
No. of Pages250
Forecast Period2022 - 2026
Estimated Market Value (USD) in 2022$0.57 billion
Forecasted Market Value (USD) by 2026$0.92 billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal

Key Topics Covered:

1. Executive Summary

2. Bacterial & Plasmid Vectors Market Characteristics

3. Bacterial & Plasmid Vectors Market Trends And Strategies

4. Bacterial & Plasmid Vectors Market - Macro Economic Scenario
4.1 COVID-19 Impact On Bacterial & Plasmid Vectors Market
4.2 Ukraine-Russia War Impact On Bacterial & Plasmid Vectors Market
4.3 Impact Of High Inflation On Bacterial & Plasmid Vectors Market

5. Bacterial & Plasmid Vectors Market Size And Growth
5.1. Global Bacterial & Plasmid Vectors Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Bacterial & Plasmid Vectors Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Bacterial & Plasmid Vectors Market Segmentation
6.1. Global Bacterial & Plasmid Vectors Market, Segmentation By Host Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • E.Coli Expression Vectors
  • Other Bacterial Expression Vectors

6.2. Global Bacterial & Plasmid Vectors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Genetics
  • Molecular biology
  • Bioinformatics
  • Other Applications

6.3. Global Bacterial & Plasmid Vectors Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Bacterial & Plasmid Vectors Market Regional And Country Analysis
7.1. Global Bacterial & Plasmid Vectors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Bacterial & Plasmid Vectors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/d7m89e

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Global Bacterial & Plasmid Vectors Market

Contact Data